First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jie Wang, M.D.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator - Myung-Ju Ahn, M.D.
Samsung Medical Center
Principal Investigator - Qing Zhou, M.D.
Guangdong Provincial People's Hospital
Principal Investigator - Yilong Wu, M.D.
Guangdong Provincial People's Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
58 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- China Site
Hefei, Anhui, China
- China Site
Chongqing, China, China
- China Site
Fuzhou, Fujian, China
- China Site
Xiamen, Fujian, China
- China Site
Guangzhou, Guangdong, China
- China Site
Guangzhou, Guangdong, China
- China Site
Haerbin, Heilongjiang, China
- China Site
Zhengzhou, Henan, China
- China Site
Zhengzhou, Henan, China
- China Site
Wuhan, Hubei, China
- China Site
Wuhan, Hubei, China
- China Site
Wuhan, Hubei, China
- China Site
Yichang, Hubei, China
- China Site
Changsha, Hunan, China
- China Site
Nanjing, Jiangsu, China
- China Site
Nanjing, Jiangsu, China
- China Site
Suzhou, Jiangsu, China
- China Site
Wuxi, Jiangsu, China
- China Site
Xuzhou, Jiangsu, China
- China Site
Yangzhou, Jiangsu, China
- China Site
Changchun, Jilin, China
- China Site
Changchun, Jilin, China
- China Site
Xi'an, Shaanxi, China
- China Site 0123
Jinan, Shandong, China
- China Site
Linyi, Shandong, China
- China Site
Weifang, Shandong, China
- China Site
Yantai, Shandong, China
- China Site
Chengdu, Sichuan, China
- China Site
Kunming, Yunnan, China
- China Site
Hangzhou, Zhejiang, China
- China Site
Hangzhou, Zhejiang, China
- China Site
Hangzhou, Zhejiang, China
- China Site
Beijing, China
- China Site
Beijing, China
- China Site
Beijing, China
- China Site
Beijing, China
- China Site
Chongqing, China
- China Site
Chongqing, China
- China Site
Shanghai, China
- China Site
Shanghai, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Oct 2018
- Primary completion
- 12 Jul 2022
- Completion
- 12 Jul 2022
- Last update posted
- 10 Sept 2025
- Registered enrollment
- 492
- Registry id
- NCT03653546
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.